BioSig Technologies Inc Stock Price, News & Analysis

BioSig Technologies announced a definitive purchase agreement for the sale of $3 million in common stock and warrants, led by a family office specializing in small cap emerging growth investments. The agreement involves issuing 2,611,739 shares at $1.15 each, along with warrants to purchase the same number of shares at $1.40. Proceeds will support working capital and the commercialization of the PURE EP™ System. The offering is expected to close around March 23, 2022, pending customary conditions. This funding aims to provide sufficient operating capital for the company's ongoing business plan.

BioSig Technologies has appointed John Sieckhaus as Chief Operating Officer, boosting its operational capabilities. Sieckhaus, with 30 years in healthcare, previously held senior roles at St. Jude Medical and Abbott, driving significant revenue growth. His expertise will enhance the rollout of the PURE EP™ System, which is FDA-cleared and aims to optimize cardiac electrophysiology procedures. The system has already been used in over 2150 patient cases, showing a 75% improvement in signal quality compared to conventional methods.

BioSig Technologies, Inc. (NASDAQ: BSGM) announced the allowance of a new utility patent for its PURE EP™ noise-filtering technology aimed at improving cardiac signal fidelity. This patent (17/091,357), filed on November 6, 2020, expands the company's portfolio to 49 issued or allowed patents globally. The PURE EP™ System enhances the clarity of ECG and intra-cardiac signals, crucial for treating complex arrhythmias like atrial fibrillation. This advancement underscores the platform's clinical significance, addressing a critical need in electrophysiology.

BioSig Technologies (NASDAQ: BSGM) announced that its PURE EP™ System will be highlighted at the 27th Annual International Atrial Fibrillation Symposium from January 13-15, 2022. Dr. DJ Lakkireddy will present during a Spotlight Session on January 13, showcasing clinical observations and advancements in arrhythmia care. More than 73 physicians have utilized the system in over 1800 patient cases. The company aims to expand its commercial launch in the Northeast, Texas, and Florida, with recent clinical data showing a 75% improvement in intracardiac signal quality.

BioSig Technologies concluded 2021 with over 1,800 patient cases utilizing the PURE EP™ System. The company will present at the 24th Annual Virtual Needham Growth Conference on January 14, 2022, at 4:15 PM ET. The PURE EP™ System, an FDA-cleared Class II device, enhances procedural efficiency in cardiac electrophysiology. Recent study results published in the Journal of Cardiovascular Electrophysiology confirmed a 75% improvement in signal quality. With one in 18 Americans affected by cardiac arrhythmias and increasing atrial fibrillation rates, BioSig's technology addresses a significant healthcare challenge.

BioSig Technologies (Nasdaq: BSGM) has appointed Access Strategy Partners to enhance its market access strategy for the PURE EP™ System, a signal processing technology aimed at improving arrhythmia care. Access Strategy Partners brings over 30 years of medical device commercialization expertise, led by Jim Walker. This collaboration will focus on economic value modeling and hospital engagement to accelerate commercialization. The PURE EP™ System has shown promising clinical results, with a 75% improvement in signal quality reported.

BioSig Technologies announces the installation of its PURE EP™ System at HCA Healthcare-operated Westside Regional Medical Center in Florida to enhance arrhythmia care. This facility, recognized for its electrophysiology program, adds to BioSig's clinical reach in Florida, which now includes partnerships with notable centers like Mayo Clinic. Over 73 physicians have utilized the PURE EP™ System in more than 1750 patient cases, showing a 75% improvement in signal quality, critical for cardiac procedures.

BioSig Technologies (Nasdaq: BSGM) announced a conference call scheduled for December 21, 2021, at 2 PM ET to discuss its innovative signal processing platform aimed at improving ECG and intra-cardiac signal fidelity. The call will be accessible via U.S. toll-free and international numbers. The PURE EP (tm) System, BioSig's FDA-cleared device, has shown a 75% improvement in signal quality in clinical studies. With increasing cases of atrial fibrillation, the company aims to enhance cardiac care efficiency. A webcast replay will be available following the call.

BioSig Technologies, Inc. (Nasdaq: BSGM) announced that Executive Vice President Natasha Drapeau will present at the Benzinga All Access event on December 14, 2021, at 9:40 am EST. The company has seen solid performance with the first commercial sales of its PURE EP™ System, completing approximately 1800 patient cases. The device aims to enhance cardiac signal quality, with clinical data showing a 75% improvement over conventional sources. Atrial fibrillation affects millions and incurs significant healthcare costs, highlighting the demand for innovative solutions.